PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEstropipate
Estropipate
Ogen (estropipate) is a small molecule pharmaceutical. Estropipate was first approved as Ogen 5 on 1982-01-01. It is used to treat hot flashes, hypogonadism, menopause, menorrhagia, and premature menopause amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
reproductive and urinary physiological phenomenaD012101
Trade Name
FDA
EMA
Ogen (discontinued: Estropipate, Ogen, Ortho-est)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
estropipateANDA2012-03-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
menorrhagiaEFO_0003945D008595N92.0
primary ovarian insufficiencyEFO_0004266D016649E28.3
hot flashesD019584
hypogonadismD007006E23.0
premature menopauseD008594E28.31
menopauseEFO_0003922D008593N95
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD01381011
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEstropipate
INN
Description
Estropipate is a steroid sulfate and a piperazinium salt. It is functionally related to an estrone.
Classification
Small molecule
Drug classestrogens; atropine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O
Identifiers
PDB
CAS-ID7280-37-7
RxCUI
ChEMBL IDCHEMBL1200980
ChEBI ID
PubChem CID5284555
DrugBankDB04574
UNII ID
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Estropipate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 104 documents
View more details
Safety
Black-box Warning
Black-box warning for: Estropipate
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
731 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use